SLC1A2 and relapsing-remitting multiple sclerosis: Interestingly, when remitting RRMS patients were subdivided in untreated or DMT-treated patient groups, only the untreated group showed a significant increase of plasma EV-EAAT2 levels respect to healthy controls.